Search

Your search keyword '"Itaha H"' showing total 7 results
Start Over Author "Itaha H" Language japanese
7 results on '"Itaha H"'

1. [Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2009].

Author

Yamaguchi K, Ishii Y, Iwata M, Watanabe N, Shinagawa M, Yasujima M, Suwabe A, Kuroda M, Kaku M, Kitagawa M, Kanemitsu K, Imafuku Y, Murakami M, Yomodu S, Taniguchi N, Yamada T, Nomura F, Kanno H, Maesaki S, Hashikita G, Kondo S, Misawa S, Horiuchi H, Tazawa Y, Nakashima H, Takemura H, Okada M, Horikawa Y, Maekawa M, Nagura O, Yagi T, Baba H, Ishigo S, Fujita N, Komori T, Ichiyama S, Yamanaka K, Murata Y, Matsuo S, Kohno H, Kawano S, Kinoshita S, Taminato T, Negayama K, Murase M, Miyamoto H, Kusano N, Nose M, Yokozaki M, Itaha H, Matsunaga A, Yoshimura H, Kohno S, Yanagihara K, Matsuda J, Saikawa T, and Hiramatsu K

Subjects
Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Dosage Forms, Drug Resistance, Bacterial, Humans, Infant, Infant, Newborn, Japan, Meropenem, Middle Aged, Respiratory System microbiology, Time Factors, Urine microbiology, Young Adult, Anti-Bacterial Agents pharmacology, Bacteria, Anaerobic drug effects, Bacteria, Anaerobic isolation & purification, Bacterial Infections microbiology, Gram-Negative Bacteria drug effects, Gram-Negative Bacteria isolation & purification, Gram-Positive Bacteria drug effects, Gram-Positive Bacteria isolation & purification, Thienamycins pharmacology
Abstract

The antibacterial activity of meropenem (MEPM) and other parenteral antibiotics against clinical isolates of 2655 strains including 810 strains of Gram-positive bacteria, 1635 strains of Gram-negative bacteria, and 210 strains of anaerobic bacteria obtained from 30 medical institutions during 2009 was examined. The results were as follows; (1) MEPM was more active than the other carbapenem antibiotics tested against Gram-negative bacteria, especially against enterobacteriaceae and Haemophilus influenzae. MEPM was also active against most of the species tested in Gram-positive and anaerobic bacteria, except for multidrug resistant strains including methicillin-resistant Staphylococcus aureus (MRSA). (2) MEPM maintained potent and stable antibacterial activity against Pseudomonas aeruginosa. The proportion of MEPM-resistant strains to ciprofloxacin-resistant strains or imipenem-resistant strains were 53.1% and 58.0% respectively. (3) The proportion of extended-spectrum beta-lactamase (ESBL) strains was 3.1% (26 strains) in enterobacteriaceae. And the proportion of metallo-beta-lactamase strains was 2.0% (6 strains) in P. aeruginosa. (4) Of all species tested, there were no species except for Bacteroides fragilis group, which MIC90 of MEPM was more than 4-fold higher than those in our previous study. Therefore, there is almost no significant decrease in susceptibility of clinical isolates to meropenem. In conclusion, the results from this surveillance study suggest that MEPM retains its potent and broad antibacterial activity and therefore is a clinically useful carbapenem for serious infections treatment at present, 14 years passed after available for commercial use in Japan.

Published
2011

2. [Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2006].

Author

Yamaguchi K, Ishii Y, Iwata M, Watanabe N, Uehara N, Yasujima M, Kasai T, Suwabe A, Yamahata K, Kaku M, Kanemitsu K, Imafuku Y, Nishiyama K, Murakami M, Yomoda S, Taniguchi N, Yamada T, Nomura F, Watanabe M, Kanno H, Aihara M, Maesaki S, Hashikita G, Kondo S, Misawa S, Horiuchi H, Tazawa Y, Nakashima H, Takemura H, Okada M, Yamazaki F, Horii T, Maekawa M, Baba H, Ishigo S, Fujita N, Komori T, Ichiyama S, Iinuma Y, Maeda S, Yamanaka K, Murata Y, Matsuo S, Kohno H, Kinoshita S, Fujita J, Negayama K, Murase M, Miyamoto H, Kusano N, Mihara E, Itaha H, Ono J, Yoshimura H, Yanagihara K, Matsuda J, Saikawa T, and Hiramatsu K

Subjects
Drug Resistance, Bacterial, Gram-Negative Bacteria enzymology, Gram-Negative Bacteria isolation & purification, Gram-Negative Bacterial Infections microbiology, Gram-Positive Bacteria enzymology, Gram-Positive Bacteria isolation & purification, Gram-Positive Bacterial Infections microbiology, Humans, Injections, Intravenous, Japan, Meropenem, Time Factors, beta-Lactamases biosynthesis, Anti-Bacterial Agents pharmacology, Gram-Negative Bacteria drug effects, Gram-Positive Bacteria drug effects, Thienamycins pharmacology
Abstract

The antibacterial activity of meropenem (MEPM) and other parenteral antibiotics against clinical isolates of 876 strains of Gram-positive bacteria, 1764 strains of Gram-negative bacteria, and 198 strains of anaerobic bacteria obtained from 30 medical institutions during 2006 was measured. The results were as follows; 1. MEPM was more active than the other carbapenem antibiotics tested against Gram-negative bacteria, especially against enterobacteriaceae and Haemophilus influenzae. MEPM was also active against most of the species tested in Gram-positive and anaerobic bacteria, except for multi-drug resistant strains including methicillin-resistant Staphylococcus aureus. 2. As for Pseudomonas aeruginosa, all of the MEPM-resistant strains were resistant to imipenem (IPM). MEPM showed low cross-resistant rate both againt IPM-resistant P. aeruginosa (41.8%) and ciprofloxacin-resistant P. aeruginosa (33.3%). 3. The proportion of extended-spectrum beta-lactamase (ESBL) strains was 4.3% (6 strains) in Escherichia coli, 1.1% (1 strain) in Citrobacter freundii, 21.7% (5 strains) in Citrobacter koseri, 3.1% (4 strains) in Klebsiella pneumoniae, 3.3% (3 strains) in Enterobacter cloacae, 0.8% (1 strain) in Serratia marcescens, and 4.9% (2 strains) in Providencia spp. The proportion of metallo-beta-lactamase strains was 3.1% (10 strains) in P. aeruginosa. 4. Of all species tested, there were no species, which MIC90 of MEPM was more than 4-fold higher than those in our previous study. Therefore, there is almost no significant decrease in susceptibility of clinical isolates to meropenem. In conclusion, the results from this surveillance study suggest that MEPM retains its potent and broad antibacterial activity and therefore is a clinically useful carbapenem at present, 11 years after available for commercial use.

Published
2007

3. [Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2004].

Author

Yamaguchi K, Murakami M, Takahashi A, Ishii Y, Iwata M, Itoh K, Oohara T, Watanabe N, Uehara N, Nomura F, Watanabe M, Yasujima M, Kasai T, Kanno H, Aihara M, Suwabe A, Yamahata K, Maesaki S, Hashikita G, Kaku M, Kanemitsu K, Miyake K, Oguri T, Yoshida H, Nishiyama K, Okada J, Tazawa Y, Komatsu M, Nakashima H, Takemura H, Kinoshita S, Okada M, Kobayashi S, Taminato T, Negayama K, Horii T, Murase M, Miyamoto H, Baba H, Kusano N, Mihara E, Ishigo S, Kambe M, Itaha H, Fujita N, Komori T, Ono J, Yoshimura H, Ichiyama S, Maeda S, Hirakata Y, Matsuda J, Yamanaka K, Mutara Y, Saikawa T, Hiramatsu K, and Taminato S

Subjects
Anti-Infective Agents administration & dosage, Carbapenems pharmacology, Drug Resistance, Multiple, Bacterial, Injections, Intravenous, Meropenem, Thienamycins administration & dosage, Anti-Infective Agents pharmacology, Bacteria, Anaerobic drug effects, Drug Resistance, Bacterial, Gram-Negative Bacteria drug effects, Gram-Positive Bacteria drug effects, Thienamycins pharmacology
Abstract

The antibacterial activity of meropenem (MEPM) and other parenteral antibiotics against clinical isolates of 907 strains of Gram-positive bacteria, 1790 strains of Gram-negative bacteria, and 192 strains of anaerobic bacteria obtained from 30 medical institutions during 2004 was measured. The results were as follows; 1. MIC90 of MEPM for almost all of enterobacteriaceae and Haemophilus influenzae were 4-fold to 32-fold lower than those of other carbapenems. MEPM was more active than other carbapenem antibiotics against Gram-negative bacteria, especially against enterobacteriaceae and H. influenzae. MEPM were active against most of the species tested in Gram-positive and anaerobic bacteria, except for multi-drug resistant strains including methicillin-resistant Staphylococcus aureus. 2. As for Pseudomonas aeruginosa, imipenem (IPM) showed high cross-resistant rate againt meropenem-resistant P. aeruginosa (87.9%). MEPM showed low cross-resistant rate both againt IPM-resistant P. aeruginosa (49.2%) and ciprofloxacin-resistant P. aeruginosa (38.0%). 3. The proportion of extended-spectrum beta-lactamase (ESBL) strains was 3.1% (4 strains) in Escherichia coli, 8.0% (2 strains) in Citrobacter koseri, 2.5% (3 strains) in Klebsiella pneumoniae, 2.5% (2 strains) in Enterobacter cloacae, 0.9% (1 strains) in Serratia marcescens, and 2.2% (2 strains) in Proteus mirabilis. The proportion of metallo-beta-lactamase strains was 1.6% (5 strains) in P. aeruginosa. 4. Of all species tested, Peptostreptococcus spp. was the only species, which MIC90 of MEPM was more than 4-fold higher than that in our previous study using clinical isolates during 2002 (0.25 microg/ml --> 1 microg/ml). Therefore, there is almost no siginificant decrease in susceptibility of clinical isolates to meropenem. In conclusion, the results from this surveillance study suggest that MEPM retains its potent and broad antibacterial activity and therefore is a clinically useful carbapenem at present, 9 years after available for commercial use.

Published
2005

4. [Pharmaceutical and pharmacological evaluation of Burow's solution (aluminum acetate solution), hospital preparation, and development of its rapid preparation method].

Author

Ishibashi Y, Murakami T, Yumoto R, Sakai M, Shintani H, Itaha H, Kanbe M, Masuda S, Yajin K, Kihira K, and Takano M

Subjects
Acetates chemistry, Chemistry, Pharmaceutical, Dose-Response Relationship, Drug, Drug Resistance, Bacterial, Methicillin Resistance, Staphylococcus aureus drug effects, Acetates pharmacology, Technology, Pharmaceutical methods
Abstract

Burow's solution, or aluminum acetate solution, is effective in inhibiting various microorganisms including methicillin-resistant Staphylococcus aureus (MRSA) that are commonly observed in chronic suppurative otitis media. It takes several days to prepare Burow's solution using aluminum sulfate, and the pharmaceutical properties of the solution are not fully understood. In this study, the effect of storage (5 months) of Burow's solution prepared according to the Teine-Keijin Hospital manual on its pharmaceutical properties and antibacterial activities was examined. We also attempted to develop a rapid preparation method of aluminum acetate (or 1.7% aluminum) solution using two commercially available compounds of aluminum acetate basic (Al(2)O(CH(3)CO(2))(4), Al(OH)(CH(3)CO(2))(2)). The properties of Burow's solution, pH, osmolarity and antibacterial activity, were the same among different preparations and its storage for 5 months at 4 degrees C had no effect on these properties. The antibacterial potency of Burow's solution was dependent on aluminum concentration and its antibacterial potency against S. aureus and several MRSA strains was of the same magnitude. In a rapid preparation, aluminum acetate basic was mixed with appropriate amounts of tartaric acid and acetic acid, and the suspension was boiled for 2-2.5 hr until dissolved. The rapidly prepared aluminum acetate solution showed the same pharmaceutical properties and antibacterial activities as those of Burow's solution. The newly developed preparation method for aluminum acetate solution is expected to be convenient and feasible for hospital treatment of chronic suppurative otitis media.

Published
2004
Full Text
View/download PDF

5. [Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2002].

Author

Yamaguchi K, Ishii Y, Iwata M, Yoshida H, Satoh T, Watanabe N, Uehara N, Murakami M, Takahashi A, Yasujima M, Kasai T, Itoh K, Shibuya Y, Suwabe A, Obata R, Kanno H, Kubo S, Kaku M, Kanemitsu K, Maesaki S, Hashikita G, Igari J, Oguri T, Aihara M, Kinoshita S, Okada J, Tazawa Y, Taminato T, Negayama K, Nakashima H, Takemura H, Murase M, Miyamoto H, Horii T, Kusano N, Mihara E, Baba H, Ishigo S, Kambe M, Itaha H, Fujita N, Komori T, Ono J, Yoshimura H, Ichiyama S, Maeda S, Hirakata Y, Matsuda J, Yamanaka K, Murata Y, Saikawa T, and Hiramatsu K

Subjects
Bacteria isolation & purification, Bacterial Infections microbiology, Drug Resistance, Bacterial, Humans, Japan, Meropenem, Product Surveillance, Postmarketing, Time Factors, Bacteria drug effects, Carbapenems pharmacology, Thienamycins pharmacology
Abstract

The antibacterial activity of meropenem (MEPM) and other parenteral antibiotics against clinical isolates of 899 strains of Gram-positive bacteria, 1500 strains of Gram-negative bacteria, and 158 strains of anaerobic bacteria obtained from 28 medical institutions during 2002 was measured. The results were as follows; 1. MEPM was more active than other carbapenem antibiotics against Gram-negative bacteria, especially against enterobacteriaceae and Haemophilus influenzae. MIC90 of MEPM against Pseudomonas aeruginosa was the lowest of the drugs tested. MEPM showed low cross-resistant rate against both imipenem-resistant P. aeruginosa and ciprofloxacin-resistant P. aeruginosa. MEPM was active against most of the species tested in Gram-positive and anaerobic bacteria, except for multi-drug resistant strains including methicillin-resistant Staphylococcus aureus (MRSA), methicillin-resistant Staphylococcus epidermidis (MRSE). 2. The proportion of extended-spectrum beta-lactamase (ESBL) strains was 3.1% (4 strains) in Escherichia coli and 1.9% (2 strains) in Klebsiella pneumoniae. Carbapenems including MEPM were active against these ESBL strains. In conclusion, the results from this surveillance study suggest that MEPM retains its potent and broad antibacterial activity and therefore is a clinically useful carbapenem; at present, 7 years after available for commercial use.

Published
2004

6. [Probability of the standardization of control survey in local medical association].

Author

Kambe M, Ohshima T, Itaha H, Matsubara A, Ohshima I, and Maeda R

Subjects
Humans, Japan, Chemistry, Clinical standards, Clinical Laboratory Techniques standards, Quality Control, Societies, Medical
Abstract

This report discusses about the probability of the standardization of external quality control (control survey) in local medical area such as prefecture size. For example, our control survey by Hiroshima medical association in Hiroshima prefecture is selected and shown on their effort to the standardization of the control survey. This Hiroshima control survey is continuing for 27 years and its purpose is the improvement of the differences between laboratory facilities. For the all standardization of control survey system, tests, devices and reagents, the recent reports of Hiroshima control survey shows that the reference methods by Japan Society of Clinical Chemistry (JSCC) and the enzyme reference materials by Japan Committee of Clinical Laboratory Standardization (JCCLS) are very useful for the improvement of the differences between laboratory facilities in Hiroshima Prefecture.

Published
2001

7. [Results of antimicrobial susceptibilities of strains clinically isolated at 8 institutions in Hiroshima City to major oral antimicrobial drugs, mainly new quinolone drugs. Hiroshima Levofloxacin Susceptibility Surveillance Group].

Author

Fujiue Y, Kuwabara M, Muroki K, Kohara T, Itaha H, Yamasaki M, Sasaki M, Onimura K, Shigemitsu M, and Kashiyama S

Subjects
4-Quinolones, Administration, Oral, Anti-Infective Agents administration & dosage, Clarithromycin pharmacology, Drug Resistance, Microbial, Haemophilus influenzae drug effects, Humans, Lactams pharmacology, Minocycline pharmacology, Pseudomonas aeruginosa drug effects, Anti-Infective Agents pharmacology, Gram-Negative Bacteria drug effects, Gram-Positive Bacteria drug effects
Abstract

To evaluate the resistance for major oral antimicrobial agents, mainly new quinolones, we carried out a drug susceptibility surveillance of 3,050 strains of 11 microbial species clinically isolated at 8 institutions such as general hospitals and examination centers in Hiroshima city. 10 antimicrobial agents were used: 3 new quinolone drugs, 5 beta-lactam drugs, minocycline and clarithromycin. Among Gram-positive bacteria, methicillin resistant Staphylococcus aureus (MRSA) and Enterococcus faecalis showed low susceptibility to the new quinolone drugs, while methicillin susceptible Staphylococcus aureus (MSSA) and Streptococcus pneumoniae were highly sensitive to these drugs. Among Gram-negative bacteria, Pseudomonas aeruginosa showed high resistance for the new quinolone drugs, but enteric bacteria and Haemophilus influenzae did not show marked resistance, maintaining almost good sensitivity to these drugs. To reduce the appearance of resistant bacteria, appropriate antimicrobial agents should be selected. Drug susceptibility surveillance in the community will be also important in the future.

Published
2000

Catalog

Books, media, physical & digital resources
See catalog results